^
    Back
    Association details:
    Biomarker:RNF43 mutation
    Cancer:Colorectal Cancer
    Drug Class:PORCN inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    J Pathol
    Title:

    Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer

    Published date:
    01/17/2022
    Excerpt:
    ...PORCN inhibitor significantly suppressed RNF43-mutant cell-derived PDX tumor development. PORCN inhibitors are an effective therapeutic strategy against RNF43-mutant CRC development and metastasis.
    DOI:
    https://doi.org/10.1002/path.5868